Form 4: Ionis Pharmaceuticals Director Allene M. Diaz Receives Stock Options and Restricted Stock Units

Director Allene M. Diaz received stock options and restricted stock units from Ionis Pharmaceuticals on July 1, 2024, as part of the company's non-employee director compensation policy.

Summary

• On July 1, 2024, Allene M. Diaz, a director of Ionis Pharmaceuticals, received stock options and restricted stock units (RSUs) as part of the company's non-employee director compensation policy.
• The grants were adjusted to ensure that the director's annual equity compensation does not exceed $450,000, based on the aggregate grant date fair value.
• Diaz received options to purchase 10,111 shares of common stock at an exercise price of $47.11, which vest on the earlier of July 1, 2025, or the next annual meeting.
• She also received 4,079 restricted stock units, each representing a contingent right to receive one share of Ionis common stock or its equivalent cash value, vesting on the earlier of July 1, 2025, or the next annual meeting, and will be delivered on the July 15th following the vesting date.
• Following these transactions, Diaz directly owns 10,111 stock options and 8,756 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stable corporate governance and alignment of interests. The sentiment is neutral to positive.

Positives

• The equity grants align the director's interests with those of the shareholders.
• The vesting schedule encourages continued service on the board.

Future Outlook

The stock options vest on the earlier of the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, and the restricted stock units vest on the earlier of the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders of the Company, and will be delivered to the reporting person on the July 15th following the vesting date.

Industry Context

Granting stock options and restricted stock units to directors is a common practice in the pharmaceutical industry to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Director compensation packages vary widely across the pharmaceutical industry depending on company size, performance, and board responsibilities.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize a mix of cash and equity compensation for their directors.
• The specific terms of the grants, such as vesting schedules and exercise prices, are typically benchmarked against peer companies to ensure competitiveness.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially leading to better decision-making.
• The grants do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates